PRD001 has been selected for the “Strengthening Program for Pharmaceutical Startup Ecosystem” by AMED.
Our Lead project “PRD001” has been selected for the “Strengthening Program for Pharmaceutical Startup Ecosystem” by the Japan Agency for Medical Research and Development (AMED). In this Program, AMED subsidizes 2/3 of the practical development of pharmaceuticals conducted by Pharmaceutical Startups in which registered VCs invest more than 1/3 of total expenses covered by the Subsidy. English pamphlet: Here
The program will provide non-dilutive funding for the development of PRD001 through the completion of a global Phase 2 clinical trial. The combined amount raised in Series A and the AMED grant will bring the total funding to more than 5 billion yen (>30 million USD).
With this support, we will advance global development of PRD001 with the aim of contributing to lipid metabolism disorder patients around the world.